Oslo, Norway, April 29, 2025 - The Ordinary General Meeting of Lytix Biopharma
AS ("Lytix" or the "Company") was held on April 29, 2025. All proposed
resolutions on the agenda were approved.

As part of the General Meeting, a new Board of Directors was elected in line
with the recommendation from the Nomination and Compensation Committee to
further reinforce the company. The newly appointed board members bring broad and
complementary experience across business development, oncology, fundraising,
clinical development, regulatory strategy, and financial oversight. These
additions will strengthen the Lytix team and enhance Lytix's chances of quickly
bringing new therapeutic options to patients with cancer and create value for
the shareholders. 

The new board consists of the following members:

o	Eric Falcand (Chair): More than 37 years of international leadership and
management experience in the pharmaceutical industry